D. Boral Capital Reiterates Buy Rating for Immunic (NASDAQ:IMUX)

Immunic (NASDAQ:IMUX - Get Free Report)'s stock had its "buy" rating reaffirmed by analysts at D. Boral Capital in a research report issued to clients and investors on Wednesday,Benzinga reports. They currently have a $10.00 price target on the stock.

A number of other equities research analysts also recently weighed in on IMUX. William Blair reiterated an "outperform" rating on shares of Immunic in a research note on Friday, May 16th. B. Riley reissued a "buy" rating and issued a $5.00 target price (down previously from $6.00) on shares of Immunic in a research note on Friday, May 23rd. Wall Street Zen cut shares of Immunic from a "hold" rating to a "sell" rating in a research note on Thursday, March 20th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $10.00 price objective on shares of Immunic in a report on Thursday, May 1st. One equities research analyst has rated the stock with a sell rating, six have assigned a buy rating and two have given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and a consensus price target of $11.60.

Immunic Price Performance

IMUX stock opened at $0.71 on Wednesday. Immunic has a twelve month low of $0.56 and a twelve month high of $2.11. The company has a market cap of $67.84 million, a PE ratio of -0.58 and a beta of 1.48. The business's 50-day simple moving average is $0.92 and its 200 day simple moving average is $1.01.

Immunic (NASDAQ:IMUX - Get Free Report) last announced its quarterly earnings data on Thursday, May 15th. The company reported ($0.25) EPS for the quarter, hitting analysts' consensus estimates of ($0.25). On average, equities research analysts anticipate that Immunic will post -0.94 EPS for the current year.

Institutional Trading of Immunic

Large investors have recently added to or reduced their stakes in the company. Focus Partners Wealth boosted its holdings in shares of Immunic by 19.1% in the 1st quarter. Focus Partners Wealth now owns 2,583,457 shares of the company's stock worth $2,816,000 after acquiring an additional 415,104 shares in the last quarter. Aberdeen Group plc bought a new position in Immunic in the 1st quarter valued at $1,155,000. 683 Capital Management LLC boosted its stake in Immunic by 28.6% in the first quarter. 683 Capital Management LLC now owns 900,000 shares of the company's stock worth $981,000 after purchasing an additional 200,000 shares in the last quarter. Millennium Management LLC grew its holdings in shares of Immunic by 480.6% during the fourth quarter. Millennium Management LLC now owns 579,683 shares of the company's stock worth $580,000 after purchasing an additional 479,846 shares during the last quarter. Finally, Renaissance Technologies LLC grew its holdings in shares of Immunic by 45.6% during the fourth quarter. Renaissance Technologies LLC now owns 566,623 shares of the company's stock worth $567,000 after purchasing an additional 177,542 shares during the last quarter. 51.82% of the stock is owned by institutional investors.

About Immunic

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.